All In Biotech

Drug Trial Radar · NCT01103323

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Last checked: Nov 19, 2026Latest source record: Jun 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 760 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

760

Actual

Start

Apr 2010

Primary completion

Jul 2011

Study completion Jan 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Regorafenib (Stivarga, BAY73-4506)Drug

    160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

  • PlaceboDrug

    matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)

  • Best Supportive Care (BSC)Other

    BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization of the first subject until the database cut-off approximately 14 months later (19May2010 - 21Jul2011) used for 2nd planned formal interim analysis (IA).

Locations

171 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Hills, California

  • Site not named

    Orange, California

  • Site not named

    Redlands, California

  • Site not named

    Santa Maria, California

  • Site not named

    Aventura, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Peoria, Illinois

  • Site not named

    Cedar Rapids, Iowa

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Rochester, Minnesota

  • Site not named

    Saint Cloud, Minnesota

  • Site not named

    Jefferson City, Missouri

  • Site not named

    Neptune City, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Fargo, North Dakota

  • Site not named

    Toledo, Ohio

  • Site not named

    Scranton, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Sumter, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Green Bay, Wisconsin

  • Site not named

    Capital Federal-Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Site not named

    Concord, New South Wales, Australia

  • Site not named

    St Leonards, New South Wales, Australia

  • Site not named

    Woolloogabba, Queensland, Australia

  • Site not named

    Woodville South, South Australia, Australia

  • Site not named

    Footscray, Victoria, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.